Abstract
Introduction Igeneon is currently testing a humanized monoclonal antibody specific for Lewis Y (IGN311) in clinical trials of passive cancer immunotherapy. The aim of the current study is to enhance the effector function of this antibody by genetically modifying the antibody producing cell line to express the glycosyl transferase GnTIII. The presence of this enzyme leads to glycosylation of the antibody with a bi-secting N-acetyl-glucosamine group and the absence of core fucosylation.
Highlights
H Loibner1Address: 1igeneon, Vienna, Austria and 2Glycart biotechnology AG, Zürich, Switzerland
Igeneon is currently testing a humanized monoclonal antibody specific for Lewis Y (IGN311) in clinical trials of passive cancer immunotherapy
Heavy and light chain genes of IGN311 were isolated, cloned into an expression vector and transfected transiently into EBNA cells: Genes for GnTIII tranferase expression were co-transfected resulting in a new expression product; an antibody, called IGN312, with modified N-glycosylation pattern
Summary
Address: 1igeneon, Vienna, Austria and 2Glycart biotechnology AG, Zürich, Switzerland. Published: 1 July 2004 Cancer Cell International 2004, 4(Suppl 1):S22 This article is available from: http://www.cancerci.com/content/4/S1/S22. Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2nd Annual Meeting Meeting abstracts
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
